Published in Diabetes on October 01, 2014
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol (2016) 1.66
Type 2 Diabetes Mellitus and Cancer: The Role of Pharmacotherapy. J Clin Oncol (2016) 0.79
The use of exercise interventions to overcome adverse effects of androgen deprivation therapy. Nat Rev Urol (2016) 0.78
Current concepts regarding developmental mechanisms in diabetic retinopathy in Taiwan. Biomedicine (Taipei) (2016) 0.78
Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy. J Neurol (2017) 0.76
Cardiovascular effects of hormone therapy for prostate cancer. Drug Healthc Patient Saf (2015) 0.75
The Relationships between Anabolic Hormones and Body Composition in Middle-Aged and Elderly Men with Prediabetes: A Cross-Sectional Study. J Diabetes Res (2016) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
The metabolic syndrome--a new worldwide definition. Lancet (2005) 23.51
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
Adverse events associated with testosterone administration. N Engl J Med (2010) 10.94
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 8.58
Role of brain insulin receptor in control of body weight and reproduction. Science (2000) 8.14
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab (2008) 7.97
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem (2004) 7.91
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science (1988) 3.96
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab (2008) 3.67
Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med (2008) 3.66
Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci (2002) 3.64
Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci (2009) 3.22
Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08
Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care (2004) 3.07
Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab (2002) 2.76
Androgens and cardiovascular disease. Endocr Rev (2003) 2.71
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic. Diabetes (2004) 2.39
Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 2.37
Overfeeding rapidly induces leptin and insulin resistance. Diabetes (2001) 2.32
Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev (2004) 2.12
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer (2006) 2.10
Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol (2010) 2.08
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) (2003) 2.07
Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol (2009) 1.86
Insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes. Cell Metab (2006) 1.83
High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol (2011) 1.81
The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update (2009) 1.77
The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle (2011) 1.77
Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab (2011) 1.74
Androgen signaling in myocytes contributes to the maintenance of muscle mass and fiber type regulation but not to muscle strength or fatigue. Endocrinology (2009) 1.66
Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab (2006) 1.63
Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care (2011) 1.60
Transgenic rescue of insulin receptor-deficient mice. J Clin Invest (2004) 1.57
Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab (2007) 1.56
Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J Clin Invest (2005) 1.55
Activation of hypothalamic S6 kinase mediates diet-induced hepatic insulin resistance in rats. J Clin Invest (2008) 1.53
Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab (1998) 1.51
Non-genomic actions of androgens. Front Neuroendocrinol (2007) 1.48
Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation (1998) 1.47
Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) (2010) 1.46
Testosterone, body composition and aging. J Endocrinol Invest (1999) 1.42
Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol (2000) 1.38
Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab (2004) 1.36
Insulin and leptin resistance with hyperleptinemia in mice lacking androgen receptor. Diabetes (2005) 1.33
Androgen receptor immunoreactivity in skeletal muscle: enrichment at the neuromuscular junction. J Comp Neurol (2004) 1.33
Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology (2008) 1.32
Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A (2001) 1.30
Late onset of obesity in male androgen receptor-deficient (AR KO) mice. Biochem Biophys Res Commun (2003) 1.30
Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res (2009) 1.28
Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol (2012) 1.28
Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation (1999) 1.27
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem (2009) 1.20
Androgens and obesity. Curr Opin Endocrinol Diabetes Obes (2010) 1.19
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today (2007) 1.18
Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res (1999) 1.18
Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol (2013) 1.17
Testosterone (T) enhances apoptosis-related damage in human vascular endothelial cells. Endocrinology (2002) 1.12
Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med (2006) 1.10
The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia (2002) 1.10
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes (2010) 1.09
Retracted Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab (2000) 1.08
Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. J Clin Endocrinol Metab (2005) 1.07
Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol (2005) 1.06
Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol (2008) 1.06
Hyperleptinemia without obesity in male mice lacking androgen receptor in adipose tissue. Endocrinology (2008) 1.05
Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol (2002) 1.04
Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab (2008) 1.04
Brief exposure to exogenous testosterone increases death signaling and adversely affects myocardial function after ischemia. Am J Physiol Regul Integr Comp Physiol (2006) 1.04
Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia (1992) 1.02
Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res (2003) 1.01
Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation (2001) 0.99
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Hormone receptors of the baboon cardiovascular system. Biochemical characterization of aortic and myocardial cytoplasmic progesterone receptors. Circ Res (1982) 0.98
Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care (2009) 0.98
Myocytic androgen receptor controls the strength but not the mass of limb muscles. Proc Natl Acad Sci U S A (2010) 0.98
Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res (2006) 0.97
Testosterone protects rat hearts against ischaemic insults by enhancing the effects of alpha(1)-adrenoceptor stimulation. Br J Pharmacol (2007) 0.96
Myocyte androgen receptors increase metabolic rate and improve body composition by reducing fat mass. Endocrinology (2010) 0.94
Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev (2012) 0.94
A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl (2007) 0.92
Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis (2009) 0.92
Androgen receptor functions from reverse genetic models. J Steroid Biochem Mol Biol (2003) 0.92
Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys (2005) 0.92
Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-κB-mediated PTP1B expression. Diabetes (2012) 0.92
Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl (2014) 0.91
Testosterone and coronary artery disease. Front Horm Res (2009) 0.91
Testosterone therapy, thrombophilia-hypofibrinolysis, and hospitalization for deep venous thrombosis-pulmonary embolus: an exploratory, hypothesis-generating study. Clin Appl Thromb Hemost (2013) 0.91
Enhanced vasoconstriction and reduced vasorelaxation induced by testosterone and nandrolone in hypercholesterolemic rabbits. Pharmacol Res (2004) 0.90
Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology (2010) 0.90
Testosterone is required for delayed cardioprotection and enhanced heat shock protein 70 expression induced by preconditioning. Endocrinology (2006) 0.89